Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBITDA: 2021-2025

Historic EBITDA for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $7.4 million.

  • Arcutis Biotherapeutics' EBITDA rose 118.14% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.9 million, marking a year-over-year increase of 76.94%. This contributed to the annual value of -$140.1 million for FY2024, which is 46.35% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' EBITDA is $7.4 million, which was up 146.78% from -$15.8 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' EBITDA registered a high of $7.4 million during Q3 2025, and its lowest value of -$108.1 million during Q3 2022.
  • Moreover, its 3-year median value for EBITDA was -$40.7 million (2024), whereas its average is -$39.5 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' EBITDA crashed by 89.69% in 2022, and later skyrocketed by 118.14% in 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' EBITDA (Quarterly) stood at -$71.6 million in 2021, then grew by 0.08% to -$71.5 million in 2022, then grew by 7.57% to -$66.1 million in 2023, then skyrocketed by 82.86% to -$11.3 million in 2024, then soared by 118.14% to $7.4 million in 2025.
  • Its EBITDA stands at $7.4 million for Q3 2025, versus -$15.8 million for Q2 2025 and -$25.2 million for Q1 2025.